Aurothiomalate inhibits the expression of mPGES-1 in primary human chondrocytes

References

• Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999;96:7220–5.
   PubMed Web of Science ®Google Scholar
• Stichtenoth DO, Thoren S, Bian H, Peters-Golden M, Jakobsson PJ, Crofford LJ. Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J Immunol 2001;167:469–74.
   PubMed Web of Science ®Google Scholar
• Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007;59:207–24.
   PubMed Web of Science ®Google Scholar
• Leistad L, Feuerherm AJ, Faxvaag A, Johansen B. Multiple phospholipase A2 enzymes participate in the inflammatory process in osteoarthritic cartilage. Scand J Rheumatol 2011;40:308–16.
   Google Scholar
• Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769–79.
   PubMed Web of Science ®Google Scholar
• Korotkova M, Jakobsson PJ. Characterization of mPGES-1 inhibitors. Basic Clin Pharmacol Toxicol 2014;114:64–9.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, Fitzgerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 2006;116:1391–9.
   PubMed Web of Science ®Google Scholar
• Westman M, Korotkova M, af Klint E, Stark A, Audoly LP, Klareskog L, et al. Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium. Arthritis Rheum 2004;50:1774–80.
   PubMed Web of Science ®Google Scholar
• Li X, Afif H, Cheng S, Martel-Pelletier J, Pelletier JP, Ranger P, et al. Expression and regulation of microsomal prostaglandin E synthase-1 in human osteoarthritic cartilage and chondrocytes. J Rheumatol 2005;32:887–95.
   PubMed Web of Science ®Google Scholar
• Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 2003;100:9044–9.
   PubMed Web of Science ®Google Scholar
• Koskinen A, Juslin S, Nieminen R, Moilanen T, Vuolteenaho K, Moilanen E. Adiponectin associates with markers of cartilage degradation in osteoarthritis and induces production of proinflammatory and catabolic factors through mitogen-activated protein kinase pathways. Arthritis Res Ther 2011;13:R184.
   PubMed Web of Science ®Google Scholar
• Hamalainen M, Nieminen R, Asmawi MZ, Vuorela P, Vapaatalo H, Moilanen E. Effects of flavonoids on prostaglandin E2 production and on COX-2 and mPGES-1 expressions in activated macrophages. Planta Med 2011;77:1504–11.
   PubMed Web of Science ®Google Scholar
• Gerber RC, Paulus HE, Bluestone R, Pearson CM. Clinical response and serum gold levels in chrysotherapy. Lack of correlation. Ann Rheum Dis 1972;31:308–10.
   PubMed Web of Science ®Google Scholar
• Freyberg RH, Block WD, Levey S. Metabolism, toxicity and manner of action of gold compounds used in the treatment of arthritis. I. Human plasma and synovial fluid concentration and urinary excretion of gold during and following treatment with gold sodium thiomalate, gold sodium thiosulfate, and colloidal gold sulfide. J Clin Invest 1941;20:401–12.
   PubMedGoogle Scholar
• Rantalaiho V, Puolakka K, Korpela M, Hannonen P, Mottonen T. Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis. Clin Exp Rheumatol 2012;30:S27–31.
   PubMed Web of Science ®Google Scholar
• Korotkova M, Westman M, Gheorghe KR, af Klint E, Trollmo C, Ulfgren AK, et al. Effects of antirheumatic treatments on the prostaglandin E2 biosynthetic pathway. Arthritis Rheum 2005; 52:3439–47.
   PubMedGoogle Scholar
• Kean WF, Kean IR. Clinical pharmacology of gold. Inflammopharmacology 2008;16:112–25.
   PubMedGoogle Scholar
• Penneys NS, Ziboh V, Gottlieb NL, Katz S. Inhibition of prostaglandin synthesis and human epidermal enzymes by aurothiomalate in vitro: possible actions of gold in pemphigus. J Invest Dermatol 1974;63:356–61.
   PubMedGoogle Scholar
• Nieminen R, Vuolteenaho K, Riutta A, Kankaanranta H, van der Kraan PM, Moilanen T, et al. Aurothiomalate inhibits COX-2 expression in chondrocytes and in human cartilage possibly through its effects on COX-2 mRNA stability. Eur J Pharmacol 2008;587:309–16.
   PubMedGoogle Scholar
• Nieminen R, Korhonen R, Moilanen T, Clark AR, Moilanen E. Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation: MAPK phosphatase 1 as a novel target for antirheumatic drugs. Arthritis Rheum 2010;62: 1650–9.
   PubMed Web of Science ®Google Scholar
• Kawabata A. Prostaglandin E2 and pain – an update. Biol Pharm Bull 2011;34:1170–3.
   PubMed Web of Science ®Google Scholar
• Chang HH, Meuillet EJ. Identification and development of mPGES-1 inhibitors: where we are at? Future Med Chem 2011;3:1909–34.
   PubMed Web of Science ®Google Scholar
• Park SJ, Han SG, Ahsan HM, Lee K, Lee JY, Shin JS, et al. Identification of novel mPGES-1 inhibitors through screening of a chemical library. Bioorg Med Chem Lett 2012; 22:7335–9.
   PubMedGoogle Scholar
• Norberg J, Sells E, Chang HH, Alla SR, Zhang S, Meuillet EJ. Targeting inflammation: multiple innovative ways to reduce prostaglandin E2. Pharm Pat Analyst 2013;2:265–88.
   PubMedGoogle Scholar
• Leclerc P, Idborg H, Spahiu L, Larsson C, Nekhotiaeva N, Wannberg J, et al. Characterization of a human and murine mPGES-1 inhibitor and comparison to mPGES-1 genetic deletion in mouse models of inflammation. Prostaglandins Other Lipid Mediat 2013;107:26–34.
   PubMed Web of Science ®Google Scholar
• Idborg H, Olsson P, Leclerc P, Raouf J, Jakobsson PJ, Korotkova M. Effects of mPGES-1 deletion on eicosanoid and fatty acid profiles in mice. Prostaglandins Other Lipid Mediat 2013;107:18–25.
   PubMed Web of Science ®Google Scholar